Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China
· Delayed Price · Currency is CNY 80.01
-2.14 (-2.60%)
Mar 9, 2026, 3:00 PM CST
SHA:688266 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 812.73 | 531.53 | 383.56 | 301.67 | 188.99 | Upgrade
|
| Other Revenue | - | 1.43 | 2.88 | 0.63 | 1.37 | Upgrade
|
| Revenue | 812.73 | 532.95 | 386.44 | 302.31 | 190.36 | Upgrade
|
| Revenue Growth (YoY) | 52.50% | 37.91% | 27.83% | 58.81% | 588.19% | Upgrade
|
| Cost of Revenue | - | 37.72 | 31.42 | 27.53 | 7.1 | Upgrade
|
| Gross Profit | 812.73 | 495.23 | 355.02 | 274.78 | 183.26 | Upgrade
|
| Selling, General & Admin | - | 328.9 | 264.84 | 312.66 | 216.96 | Upgrade
|
| Research & Development | - | 388 | 496.33 | 497.73 | 509.39 | Upgrade
|
| Other Operating Expenses | 978.5 | -6.87 | -9.34 | 1.05 | -40.46 | Upgrade
|
| Operating Expenses | 978.5 | 712.25 | 752.47 | 812.83 | 689.18 | Upgrade
|
| Operating Income | -165.76 | -217.02 | -397.45 | -538.06 | -505.91 | Upgrade
|
| Interest Expense | - | -28.89 | -22.55 | -12.03 | -4.42 | Upgrade
|
| Interest & Investment Income | - | 61.23 | 45.31 | 32.69 | 51.04 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.01 | -0.03 | -0.16 | 0.8 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.64 | -1.74 | -2.88 | -3.48 | -8.39 | Upgrade
|
| EBT Excluding Unusual Items | -166.41 | -186.45 | -377.6 | -521.04 | -466.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.92 | 8.73 | 2.63 | 1.74 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.02 | - | Upgrade
|
| Asset Writedown | - | - | -0.28 | -0.11 | -0.01 | Upgrade
|
| Other Unusual Items | - | 27.48 | 70.07 | 30.55 | - | Upgrade
|
| Pretax Income | -166.41 | -155.05 | -299.08 | -487.95 | -465.15 | Upgrade
|
| Income Tax Expense | -5.71 | -4.75 | -3.95 | -2.45 | -3.16 | Upgrade
|
| Earnings From Continuing Operations | -160.7 | -150.3 | -295.13 | -485.51 | -461.99 | Upgrade
|
| Minority Interest in Earnings | - | 12.47 | 16.55 | 28.18 | 10.99 | Upgrade
|
| Net Income | -160.7 | -137.83 | -278.58 | -457.33 | -451 | Upgrade
|
| Net Income to Common | -160.7 | -137.83 | -278.58 | -457.33 | -451 | Upgrade
|
| Shares Outstanding (Basic) | 263 | 265 | 256 | 239 | 240 | Upgrade
|
| Shares Outstanding (Diluted) | 263 | 265 | 256 | 239 | 240 | Upgrade
|
| Shares Change (YoY) | -0.61% | 3.71% | 6.74% | -0.19% | 2.20% | Upgrade
|
| EPS (Basic) | -0.61 | -0.52 | -1.09 | -1.91 | -1.88 | Upgrade
|
| EPS (Diluted) | -0.61 | -0.52 | -1.09 | -1.91 | -1.88 | Upgrade
|
| Free Cash Flow | - | -57.49 | -295.35 | -458.97 | -525.36 | Upgrade
|
| Free Cash Flow Per Share | - | -0.22 | -1.16 | -1.92 | -2.19 | Upgrade
|
| Gross Margin | 100.00% | 92.92% | 91.87% | 90.89% | 96.27% | Upgrade
|
| Operating Margin | -20.40% | -40.72% | -102.85% | -177.98% | -265.77% | Upgrade
|
| Profit Margin | -19.77% | -25.86% | -72.09% | -151.28% | -236.92% | Upgrade
|
| Free Cash Flow Margin | - | -10.79% | -76.43% | -151.82% | -275.98% | Upgrade
|
| EBITDA | -122.84 | -174.1 | -355.54 | -485.56 | -463.65 | Upgrade
|
| EBITDA Margin | -15.12% | -32.67% | -92.00% | -160.62% | -243.57% | Upgrade
|
| D&A For EBITDA | 42.92 | 42.92 | 41.91 | 52.5 | 42.26 | Upgrade
|
| EBIT | -165.76 | -217.02 | -397.45 | -538.06 | -505.91 | Upgrade
|
| EBIT Margin | -20.40% | -40.72% | -102.85% | -177.98% | -265.77% | Upgrade
|
| Revenue as Reported | - | 532.95 | 386.44 | 302.31 | 190.36 | Upgrade
|
| Advertising Expenses | - | 0.39 | 1.36 | 75.95 | 33.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.